Great Bay Bio

Established in 2019 and based in Hong Kong, China, Great Bay Bio, operates as a biopharmaceutical company that combines artificial intelligence (AI) technology. It has a branch office in Shenzhen and a 3000 square meters R&D centre. The company has many partners such as Boji, Chime Biologic, and Guangdong University of Technology. Great Bay Bio has applied for 30 patents. The chairman of the board as well as the co-founder, Guolong Liang, graduated from Imperial College London and Oxford University. Great Bay Bio provides AI-empowered bioprocesses solutions. It developed three platforms, AlfaCell, AlfaOPA and AlfaMedX. AlfaCell platform supports the target genes inserted into the specific points of the genomic, which reduce the uncertainties of productivity and stability in the cell line development process. AlfaMedX is a cell culture media development platform and has more than one thousand formulas. The AI platforms have been used for fusion proteins, monoclonal, antibodies, and bispecific antibody drugs. The company also provides solutions for synthetic biology, industrial enzyme preparations, and cultured meat. The company generates revenue by developing AI Antibody Drug Sequence Prediction Platform, Intelligent Cell Line Construction Platform, Intelligent Media Development Platform and Intelligent Bioprocess Development Platform.

1. Series B

   Dec 16, 2024

   Amount

   Undisclosed

   Investors

   Locked

2. Series A

   Dec 1, 2021

   Amount

   $10M

   Investors

   Locked